Predictive modeling for determination of microscopic residual disease at primary cytoreduction

An NRG Oncology/Gynecologic Oncology Group 182 Study

Neil S. Horowitz, G. Larry Maxwell, Austin Miller, Chad A. Hamilton, Bunja Rungruang, Noah Rodriguez, Scott D. Richard, Thomas C. Krivak, Jeffrey M. Fowler, David G. Mutch, Linda Van Le, Roger B. Lee, Peter Argenta, David Bender, Krishnansu S. Tewari, David Gershenson, James J. Java, Michael A. Bookman

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a prediction model for R0 to support surgeons in their clinical care decisions. Methods Demographic, pathologic, surgical, and CA125 data were collected from GOG 182 records. Patients enrolled prior to September 1, 2003 were used for the training model while those enrolled after constituted the validation data set. Univariate analysis was performed to identify significant predictors of R0 and these variables were subsequently analyzed using multivariable regression. The regression model was reduced using backward selection and predictive accuracy was quantified using area under the receiver operating characteristic area under the curve (AUC) in both the training and the validation data sets. Results Of the 3882 patients enrolled in GOG 182, 1480 had complete clinical data available for the analysis. The training data set consisted of 1007 patients (234 with R0) while the validation set was comprised of 473 patients (122 with R0). The reduced multivariable regression model demonstrated several variables predictive of R0 at cytoreduction: Disease Score (DS) (p < 0.001), stage (p = 0.009), CA125 (p < 0.001), ascites (p < 0.001), and stage-age interaction (p = 0.01). Applying the prediction model to the validation data resulted in an AUC of 0.73 (0.67 to 0.78, 95% CI). Inclusion of DS enhanced the model performance to an AUC of 0.83 (0.79 to 0.88, 95% CI). Conclusions We developed and validated a prediction model for R0 that offers improved performance over previously reported models for prediction of residual disease. The performance of the prediction model suggests additional factors (i.e. imaging, molecular profiling, etc.) should be explored in the future for a more clinically actionable tool.

Original languageEnglish (US)
Pages (from-to)49-55
Number of pages7
JournalGynecologic oncology
Volume148
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Area Under Curve
Molecular Imaging
Cytomegalovirus Infections
Ascites
ROC Curve
Demography
Survival
Datasets
Surgeons
Ovarian epithelial cancer

Keywords

  • Microscopic residual
  • Ovarian cancer

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Cite this

Horowitz, N. S., Larry Maxwell, G., Miller, A., Hamilton, C. A., Rungruang, B., Rodriguez, N., ... Bookman, M. A. (2018). Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecologic oncology, 148(1), 49-55. https://doi.org/10.1016/j.ygyno.2017.10.011

Predictive modeling for determination of microscopic residual disease at primary cytoreduction : An NRG Oncology/Gynecologic Oncology Group 182 Study. / Horowitz, Neil S.; Larry Maxwell, G.; Miller, Austin; Hamilton, Chad A.; Rungruang, Bunja; Rodriguez, Noah; Richard, Scott D.; Krivak, Thomas C.; Fowler, Jeffrey M.; Mutch, David G.; Van Le, Linda; Lee, Roger B.; Argenta, Peter; Bender, David; Tewari, Krishnansu S.; Gershenson, David; Java, James J.; Bookman, Michael A.

In: Gynecologic oncology, Vol. 148, No. 1, 01.01.2018, p. 49-55.

Research output: Contribution to journalArticle

Horowitz, NS, Larry Maxwell, G, Miller, A, Hamilton, CA, Rungruang, B, Rodriguez, N, Richard, SD, Krivak, TC, Fowler, JM, Mutch, DG, Van Le, L, Lee, RB, Argenta, P, Bender, D, Tewari, KS, Gershenson, D, Java, JJ & Bookman, MA 2018, 'Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study', Gynecologic oncology, vol. 148, no. 1, pp. 49-55. https://doi.org/10.1016/j.ygyno.2017.10.011
Horowitz, Neil S. ; Larry Maxwell, G. ; Miller, Austin ; Hamilton, Chad A. ; Rungruang, Bunja ; Rodriguez, Noah ; Richard, Scott D. ; Krivak, Thomas C. ; Fowler, Jeffrey M. ; Mutch, David G. ; Van Le, Linda ; Lee, Roger B. ; Argenta, Peter ; Bender, David ; Tewari, Krishnansu S. ; Gershenson, David ; Java, James J. ; Bookman, Michael A. / Predictive modeling for determination of microscopic residual disease at primary cytoreduction : An NRG Oncology/Gynecologic Oncology Group 182 Study. In: Gynecologic oncology. 2018 ; Vol. 148, No. 1. pp. 49-55.
@article{7948711f39574ad3b65faf26198dc958,
title = "Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study",
abstract = "Objective Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a prediction model for R0 to support surgeons in their clinical care decisions. Methods Demographic, pathologic, surgical, and CA125 data were collected from GOG 182 records. Patients enrolled prior to September 1, 2003 were used for the training model while those enrolled after constituted the validation data set. Univariate analysis was performed to identify significant predictors of R0 and these variables were subsequently analyzed using multivariable regression. The regression model was reduced using backward selection and predictive accuracy was quantified using area under the receiver operating characteristic area under the curve (AUC) in both the training and the validation data sets. Results Of the 3882 patients enrolled in GOG 182, 1480 had complete clinical data available for the analysis. The training data set consisted of 1007 patients (234 with R0) while the validation set was comprised of 473 patients (122 with R0). The reduced multivariable regression model demonstrated several variables predictive of R0 at cytoreduction: Disease Score (DS) (p < 0.001), stage (p = 0.009), CA125 (p < 0.001), ascites (p < 0.001), and stage-age interaction (p = 0.01). Applying the prediction model to the validation data resulted in an AUC of 0.73 (0.67 to 0.78, 95{\%} CI). Inclusion of DS enhanced the model performance to an AUC of 0.83 (0.79 to 0.88, 95{\%} CI). Conclusions We developed and validated a prediction model for R0 that offers improved performance over previously reported models for prediction of residual disease. The performance of the prediction model suggests additional factors (i.e. imaging, molecular profiling, etc.) should be explored in the future for a more clinically actionable tool.",
keywords = "Microscopic residual, Ovarian cancer",
author = "Horowitz, {Neil S.} and {Larry Maxwell}, G. and Austin Miller and Hamilton, {Chad A.} and Bunja Rungruang and Noah Rodriguez and Richard, {Scott D.} and Krivak, {Thomas C.} and Fowler, {Jeffrey M.} and Mutch, {David G.} and {Van Le}, Linda and Lee, {Roger B.} and Peter Argenta and David Bender and Tewari, {Krishnansu S.} and David Gershenson and Java, {James J.} and Bookman, {Michael A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ygyno.2017.10.011",
language = "English (US)",
volume = "148",
pages = "49--55",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Predictive modeling for determination of microscopic residual disease at primary cytoreduction

T2 - An NRG Oncology/Gynecologic Oncology Group 182 Study

AU - Horowitz, Neil S.

AU - Larry Maxwell, G.

AU - Miller, Austin

AU - Hamilton, Chad A.

AU - Rungruang, Bunja

AU - Rodriguez, Noah

AU - Richard, Scott D.

AU - Krivak, Thomas C.

AU - Fowler, Jeffrey M.

AU - Mutch, David G.

AU - Van Le, Linda

AU - Lee, Roger B.

AU - Argenta, Peter

AU - Bender, David

AU - Tewari, Krishnansu S.

AU - Gershenson, David

AU - Java, James J.

AU - Bookman, Michael A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a prediction model for R0 to support surgeons in their clinical care decisions. Methods Demographic, pathologic, surgical, and CA125 data were collected from GOG 182 records. Patients enrolled prior to September 1, 2003 were used for the training model while those enrolled after constituted the validation data set. Univariate analysis was performed to identify significant predictors of R0 and these variables were subsequently analyzed using multivariable regression. The regression model was reduced using backward selection and predictive accuracy was quantified using area under the receiver operating characteristic area under the curve (AUC) in both the training and the validation data sets. Results Of the 3882 patients enrolled in GOG 182, 1480 had complete clinical data available for the analysis. The training data set consisted of 1007 patients (234 with R0) while the validation set was comprised of 473 patients (122 with R0). The reduced multivariable regression model demonstrated several variables predictive of R0 at cytoreduction: Disease Score (DS) (p < 0.001), stage (p = 0.009), CA125 (p < 0.001), ascites (p < 0.001), and stage-age interaction (p = 0.01). Applying the prediction model to the validation data resulted in an AUC of 0.73 (0.67 to 0.78, 95% CI). Inclusion of DS enhanced the model performance to an AUC of 0.83 (0.79 to 0.88, 95% CI). Conclusions We developed and validated a prediction model for R0 that offers improved performance over previously reported models for prediction of residual disease. The performance of the prediction model suggests additional factors (i.e. imaging, molecular profiling, etc.) should be explored in the future for a more clinically actionable tool.

AB - Objective Microscopic residual disease following complete cytoreduction (R0) is associated with a significant survival benefit for patients with advanced epithelial ovarian cancer (EOC). Our objective was to develop a prediction model for R0 to support surgeons in their clinical care decisions. Methods Demographic, pathologic, surgical, and CA125 data were collected from GOG 182 records. Patients enrolled prior to September 1, 2003 were used for the training model while those enrolled after constituted the validation data set. Univariate analysis was performed to identify significant predictors of R0 and these variables were subsequently analyzed using multivariable regression. The regression model was reduced using backward selection and predictive accuracy was quantified using area under the receiver operating characteristic area under the curve (AUC) in both the training and the validation data sets. Results Of the 3882 patients enrolled in GOG 182, 1480 had complete clinical data available for the analysis. The training data set consisted of 1007 patients (234 with R0) while the validation set was comprised of 473 patients (122 with R0). The reduced multivariable regression model demonstrated several variables predictive of R0 at cytoreduction: Disease Score (DS) (p < 0.001), stage (p = 0.009), CA125 (p < 0.001), ascites (p < 0.001), and stage-age interaction (p = 0.01). Applying the prediction model to the validation data resulted in an AUC of 0.73 (0.67 to 0.78, 95% CI). Inclusion of DS enhanced the model performance to an AUC of 0.83 (0.79 to 0.88, 95% CI). Conclusions We developed and validated a prediction model for R0 that offers improved performance over previously reported models for prediction of residual disease. The performance of the prediction model suggests additional factors (i.e. imaging, molecular profiling, etc.) should be explored in the future for a more clinically actionable tool.

KW - Microscopic residual

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=85035002310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035002310&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.10.011

DO - 10.1016/j.ygyno.2017.10.011

M3 - Article

VL - 148

SP - 49

EP - 55

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -